{"id":979708,"date":"2020-04-16T12:04:09","date_gmt":"2020-04-16T10:04:09","guid":{"rendered":"https:\/\/frezzapartners.com\/?p=979708"},"modified":"2020-04-17T14:05:43","modified_gmt":"2020-04-17T12:05:43","slug":"leo-pharma-sottoscrive-accordo-di-licenza-oneness-biotech-e-microbio-shanghai-per-il-farmaco-fb825","status":"publish","type":"post","link":"https:\/\/frezzapartners.com\/en\/leo-pharma-sottoscrive-accordo-di-licenza-oneness-biotech-e-microbio-shanghai-per-il-farmaco-fb825\/","title":{"rendered":"LEO Pharma sottoscrive accordo di licenza con Oneness Biotech e Microbio Shanghai per il farmaco FB825"},"content":{"rendered":"<p>photo by Chris Slupski<\/p>\n<section id=\"pid-82587\">\n<section id=\"pid-82587\">\n<section id=\"pid-82587\">BALLERUP, Danimarca<strong> \u2013 <\/strong>LEO Pharma A\/S, azienda operante in area dermatologia medica, ha <a href=\"https:\/\/www.leo-pharmapro.it\/news\/leo-pharma-sottoscrive-un-accordo-di-licenza-con-oneness-biotech-e-microbio-shanghai-per-fb825-un-nuovo-farmaco-candidato-per-il-trattamento-della-dermatite-atopica-e-dellasma-di-natura-allergica\/\">annunciato<\/a> di aver sottoscritto un accordo di licenza esclusiva mondiale con Oneness Biotech (Taiwan) e Microbio Shanghai (Cina) per lo sviluppo e la commercializzazione di un nuovo farmaco (FB825) candidato per la cura della dermatite atopica (AD) e dell\u2019asma di natura allergica.<span id=\"more-1217\"><\/span>FB825 \u00e8 una molecola capostipite di una nuova classe terapeutica con un meccanismo di azione unico (MoA) mirato al dominio CEmX della membrana che circonda le lgE (mlgE) che causa una deplezione delle cellule B mlgE positive. Questo nuovo meccanismo d\u2019azione per il trattamento della dermatite atopica dovrebbe ridurre il carico della malattia riducendo i mediatori dell\u2019infiammazione, cos\u00ec come i livelli di lgE.<\/p>\n<p>\u201c<em>Dopo aver visto i primi dati del trattamento con FB825 sull\u2019uomo e la riduzione dell\u2019 EASI (Eczema Area and Severity Index, un indicatore di gravit\u00e0 della dermatite atopica), crediamo che stia arrivando nella nostra pipeline di sviluppo un nuovo e promettente farmaco<\/em>,\u201d ha commentato il Dr. Kim Kjoeller, Executive Vice President, Global Resarch &amp; Development, LEO Pharma. \u201c<em>Non esistono due pazienti uguali, e poich\u00e9 esistono ancora dei forti bisogni insoddisfatti, ci impegniamo a costruire una pipeline diversificata che contenga una vasta gamma di molecole e di meccanismi di azione<\/em>\u201d.<\/p>\n<p>Secondo l\u2019accordo, Oneness sar\u00e0 responsabile dell\u2019esecuzione dello studio di Fase 2a per la dermatite atopica negli Stati Uniti e Microbio Shanghai eseguir\u00e0 lo studio di Fase 2a per l\u2019asma di tipo allergico in Cina. LEO Pharma si assumer\u00e0 tutte le responsabilit\u00e0 dello sviluppo di tutti gli studi che seguiranno la Fase 2a.<\/p>\n<\/section>\n<\/section>\n<\/section>\n<h1><\/h1>\n<p><strong>\u00a0<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>photo by Chris Slupski BALLERUP, Danimarca \u2013 LEO Pharma A\/S, azienda operante in area dermatologia medica, ha annunciato di aver sottoscritto un accordo di licenza esclusiva mondiale con Oneness Biotech (Taiwan) e Microbio Shanghai (Cina) per lo sviluppo e la commercializzazione di un nuovo farmaco (FB825) candidato per la cura della dermatite atopica (AD) e dell\u2019asma di natura allergica.FB825 \u00e8 una molecola capostipite di una nuova classe terapeutica con un meccanismo di azione unico (MoA) mirato al dominio CEmX della&#8230;<\/p>\n","protected":false},"author":297440,"featured_media":979709,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[141],"tags":[2727,2726,2623,2725],"class_list":["post-979708","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-accordo","tag-dermatologia","tag-farmaco","tag-leo-pharma"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>LEO Pharma sottoscrive accordo di licenza con Oneness Biotech e Microbio Shanghai per il farmaco FB825 - Frezza Partners<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/frezzapartners.com\/leo-pharma-sottoscrive-accordo-di-licenza-oneness-biotech-e-microbio-shanghai-per-il-farmaco-fb825\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"LEO Pharma sottoscrive accordo di licenza con Oneness Biotech e Microbio Shanghai per il farmaco FB825 - Frezza Partners\" \/>\n<meta property=\"og:description\" content=\"photo by Chris Slupski BALLERUP, Danimarca \u2013 LEO Pharma A\/S, azienda operante in area dermatologia medica, ha annunciato di aver sottoscritto un accordo di licenza esclusiva mondiale con Oneness Biotech (Taiwan) e Microbio Shanghai (Cina) per lo sviluppo e la commercializzazione di un nuovo farmaco (FB825) candidato per la cura della dermatite atopica (AD) e dell\u2019asma di natura allergica.FB825 \u00e8 una molecola capostipite di una nuova classe terapeutica con un meccanismo di azione unico (MoA) mirato al dominio CEmX della...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/frezzapartners.com\/leo-pharma-sottoscrive-accordo-di-licenza-oneness-biotech-e-microbio-shanghai-per-il-farmaco-fb825\/\" \/>\n<meta property=\"og:site_name\" content=\"Frezza Partners\" \/>\n<meta property=\"article:published_time\" content=\"2020-04-16T10:04:09+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-04-17T12:05:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/frezzapartners.com\/wp-content\/uploads\/2020\/04\/chris-slupski-ckMxc3LxhMo-unsplash-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1707\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Frezza Partners\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Frezza Partners\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/leo-pharma-sottoscrive-accordo-di-licenza-oneness-biotech-e-microbio-shanghai-per-il-farmaco-fb825\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/leo-pharma-sottoscrive-accordo-di-licenza-oneness-biotech-e-microbio-shanghai-per-il-farmaco-fb825\\\/\"},\"author\":{\"name\":\"Frezza Partners\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/#\\\/schema\\\/person\\\/b953d1492c9f06a9923aed3b3cbe9fc0\"},\"headline\":\"LEO Pharma sottoscrive accordo di licenza con Oneness Biotech e Microbio Shanghai per il farmaco FB825\",\"datePublished\":\"2020-04-16T10:04:09+00:00\",\"dateModified\":\"2020-04-17T12:05:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/leo-pharma-sottoscrive-accordo-di-licenza-oneness-biotech-e-microbio-shanghai-per-il-farmaco-fb825\\\/\"},\"wordCount\":285,\"image\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/leo-pharma-sottoscrive-accordo-di-licenza-oneness-biotech-e-microbio-shanghai-per-il-farmaco-fb825\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/frezzapartners.com\\\/wp-content\\\/uploads\\\/2020\\\/04\\\/chris-slupski-ckMxc3LxhMo-unsplash-scaled.jpg\",\"keywords\":[\"accordo\",\"dermatologia\",\"farmaco\",\"leo pharma\"],\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/leo-pharma-sottoscrive-accordo-di-licenza-oneness-biotech-e-microbio-shanghai-per-il-farmaco-fb825\\\/\",\"url\":\"https:\\\/\\\/frezzapartners.com\\\/leo-pharma-sottoscrive-accordo-di-licenza-oneness-biotech-e-microbio-shanghai-per-il-farmaco-fb825\\\/\",\"name\":\"LEO Pharma sottoscrive accordo di licenza con Oneness Biotech e Microbio Shanghai per il farmaco FB825 - Frezza Partners\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/leo-pharma-sottoscrive-accordo-di-licenza-oneness-biotech-e-microbio-shanghai-per-il-farmaco-fb825\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/leo-pharma-sottoscrive-accordo-di-licenza-oneness-biotech-e-microbio-shanghai-per-il-farmaco-fb825\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/frezzapartners.com\\\/wp-content\\\/uploads\\\/2020\\\/04\\\/chris-slupski-ckMxc3LxhMo-unsplash-scaled.jpg\",\"datePublished\":\"2020-04-16T10:04:09+00:00\",\"dateModified\":\"2020-04-17T12:05:43+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/#\\\/schema\\\/person\\\/b953d1492c9f06a9923aed3b3cbe9fc0\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/leo-pharma-sottoscrive-accordo-di-licenza-oneness-biotech-e-microbio-shanghai-per-il-farmaco-fb825\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/frezzapartners.com\\\/leo-pharma-sottoscrive-accordo-di-licenza-oneness-biotech-e-microbio-shanghai-per-il-farmaco-fb825\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/leo-pharma-sottoscrive-accordo-di-licenza-oneness-biotech-e-microbio-shanghai-per-il-farmaco-fb825\\\/#primaryimage\",\"url\":\"https:\\\/\\\/frezzapartners.com\\\/wp-content\\\/uploads\\\/2020\\\/04\\\/chris-slupski-ckMxc3LxhMo-unsplash-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/frezzapartners.com\\\/wp-content\\\/uploads\\\/2020\\\/04\\\/chris-slupski-ckMxc3LxhMo-unsplash-scaled.jpg\",\"width\":2560,\"height\":1707},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/leo-pharma-sottoscrive-accordo-di-licenza-oneness-biotech-e-microbio-shanghai-per-il-farmaco-fb825\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/frezzapartners.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"LEO Pharma sottoscrive accordo di licenza con Oneness Biotech e Microbio Shanghai per il farmaco FB825\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/#website\",\"url\":\"https:\\\/\\\/frezzapartners.com\\\/\",\"name\":\"Frezza Partners\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/frezzapartners.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/frezzapartners.com\\\/#\\\/schema\\\/person\\\/b953d1492c9f06a9923aed3b3cbe9fc0\",\"name\":\"Frezza Partners\",\"url\":\"https:\\\/\\\/frezzapartners.com\\\/en\\\/author\\\/fr3zz4partn3rs\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"LEO Pharma sottoscrive accordo di licenza con Oneness Biotech e Microbio Shanghai per il farmaco FB825 - Frezza Partners","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/frezzapartners.com\/leo-pharma-sottoscrive-accordo-di-licenza-oneness-biotech-e-microbio-shanghai-per-il-farmaco-fb825\/","og_locale":"en_US","og_type":"article","og_title":"LEO Pharma sottoscrive accordo di licenza con Oneness Biotech e Microbio Shanghai per il farmaco FB825 - Frezza Partners","og_description":"photo by Chris Slupski BALLERUP, Danimarca \u2013 LEO Pharma A\/S, azienda operante in area dermatologia medica, ha annunciato di aver sottoscritto un accordo di licenza esclusiva mondiale con Oneness Biotech (Taiwan) e Microbio Shanghai (Cina) per lo sviluppo e la commercializzazione di un nuovo farmaco (FB825) candidato per la cura della dermatite atopica (AD) e dell\u2019asma di natura allergica.FB825 \u00e8 una molecola capostipite di una nuova classe terapeutica con un meccanismo di azione unico (MoA) mirato al dominio CEmX della...","og_url":"https:\/\/frezzapartners.com\/leo-pharma-sottoscrive-accordo-di-licenza-oneness-biotech-e-microbio-shanghai-per-il-farmaco-fb825\/","og_site_name":"Frezza Partners","article_published_time":"2020-04-16T10:04:09+00:00","article_modified_time":"2020-04-17T12:05:43+00:00","og_image":[{"width":2560,"height":1707,"url":"https:\/\/frezzapartners.com\/wp-content\/uploads\/2020\/04\/chris-slupski-ckMxc3LxhMo-unsplash-scaled.jpg","type":"image\/jpeg"}],"author":"Frezza Partners","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Frezza Partners","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/frezzapartners.com\/leo-pharma-sottoscrive-accordo-di-licenza-oneness-biotech-e-microbio-shanghai-per-il-farmaco-fb825\/#article","isPartOf":{"@id":"https:\/\/frezzapartners.com\/leo-pharma-sottoscrive-accordo-di-licenza-oneness-biotech-e-microbio-shanghai-per-il-farmaco-fb825\/"},"author":{"name":"Frezza Partners","@id":"https:\/\/frezzapartners.com\/#\/schema\/person\/b953d1492c9f06a9923aed3b3cbe9fc0"},"headline":"LEO Pharma sottoscrive accordo di licenza con Oneness Biotech e Microbio Shanghai per il farmaco FB825","datePublished":"2020-04-16T10:04:09+00:00","dateModified":"2020-04-17T12:05:43+00:00","mainEntityOfPage":{"@id":"https:\/\/frezzapartners.com\/leo-pharma-sottoscrive-accordo-di-licenza-oneness-biotech-e-microbio-shanghai-per-il-farmaco-fb825\/"},"wordCount":285,"image":{"@id":"https:\/\/frezzapartners.com\/leo-pharma-sottoscrive-accordo-di-licenza-oneness-biotech-e-microbio-shanghai-per-il-farmaco-fb825\/#primaryimage"},"thumbnailUrl":"https:\/\/frezzapartners.com\/wp-content\/uploads\/2020\/04\/chris-slupski-ckMxc3LxhMo-unsplash-scaled.jpg","keywords":["accordo","dermatologia","farmaco","leo pharma"],"articleSection":["News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/frezzapartners.com\/leo-pharma-sottoscrive-accordo-di-licenza-oneness-biotech-e-microbio-shanghai-per-il-farmaco-fb825\/","url":"https:\/\/frezzapartners.com\/leo-pharma-sottoscrive-accordo-di-licenza-oneness-biotech-e-microbio-shanghai-per-il-farmaco-fb825\/","name":"LEO Pharma sottoscrive accordo di licenza con Oneness Biotech e Microbio Shanghai per il farmaco FB825 - Frezza Partners","isPartOf":{"@id":"https:\/\/frezzapartners.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/frezzapartners.com\/leo-pharma-sottoscrive-accordo-di-licenza-oneness-biotech-e-microbio-shanghai-per-il-farmaco-fb825\/#primaryimage"},"image":{"@id":"https:\/\/frezzapartners.com\/leo-pharma-sottoscrive-accordo-di-licenza-oneness-biotech-e-microbio-shanghai-per-il-farmaco-fb825\/#primaryimage"},"thumbnailUrl":"https:\/\/frezzapartners.com\/wp-content\/uploads\/2020\/04\/chris-slupski-ckMxc3LxhMo-unsplash-scaled.jpg","datePublished":"2020-04-16T10:04:09+00:00","dateModified":"2020-04-17T12:05:43+00:00","author":{"@id":"https:\/\/frezzapartners.com\/#\/schema\/person\/b953d1492c9f06a9923aed3b3cbe9fc0"},"breadcrumb":{"@id":"https:\/\/frezzapartners.com\/leo-pharma-sottoscrive-accordo-di-licenza-oneness-biotech-e-microbio-shanghai-per-il-farmaco-fb825\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/frezzapartners.com\/leo-pharma-sottoscrive-accordo-di-licenza-oneness-biotech-e-microbio-shanghai-per-il-farmaco-fb825\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/frezzapartners.com\/leo-pharma-sottoscrive-accordo-di-licenza-oneness-biotech-e-microbio-shanghai-per-il-farmaco-fb825\/#primaryimage","url":"https:\/\/frezzapartners.com\/wp-content\/uploads\/2020\/04\/chris-slupski-ckMxc3LxhMo-unsplash-scaled.jpg","contentUrl":"https:\/\/frezzapartners.com\/wp-content\/uploads\/2020\/04\/chris-slupski-ckMxc3LxhMo-unsplash-scaled.jpg","width":2560,"height":1707},{"@type":"BreadcrumbList","@id":"https:\/\/frezzapartners.com\/leo-pharma-sottoscrive-accordo-di-licenza-oneness-biotech-e-microbio-shanghai-per-il-farmaco-fb825\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/frezzapartners.com\/"},{"@type":"ListItem","position":2,"name":"LEO Pharma sottoscrive accordo di licenza con Oneness Biotech e Microbio Shanghai per il farmaco FB825"}]},{"@type":"WebSite","@id":"https:\/\/frezzapartners.com\/#website","url":"https:\/\/frezzapartners.com\/","name":"Frezza Partners","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/frezzapartners.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/frezzapartners.com\/#\/schema\/person\/b953d1492c9f06a9923aed3b3cbe9fc0","name":"Frezza Partners","url":"https:\/\/frezzapartners.com\/en\/author\/fr3zz4partn3rs\/"}]}},"_links":{"self":[{"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/posts\/979708","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/users\/297440"}],"replies":[{"embeddable":true,"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/comments?post=979708"}],"version-history":[{"count":0,"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/posts\/979708\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/media\/979709"}],"wp:attachment":[{"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/media?parent=979708"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/categories?post=979708"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/frezzapartners.com\/en\/wp-json\/wp\/v2\/tags?post=979708"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}